February 26, 2020 / 8:28 AM / a month ago

BRIEF-Kiadis Pharma Gets FDA Clearance Of Clinical Study in Leukemia

Feb 26 (Reuters) - Kiadis Pharma NV:

* KIADIS PHARMA ANNOUNCES FDA CLEARANCE OF CLINICAL STUDY BY THE OHIO STATE UNIVERSITY IN R/R AML WITH OFF-THE-SHELF NK CELLS FROM UNIVERSAL DONORS

* TRIAL IS EXPECTED TO PROVIDE FURTHER CLINICAL PROOF-OF-CONCEPT OF KIADIS’ K-NK003 PRODUCT

* OSUCCC - JAMES TEAM RECEIVED FDA APPROVAL FOR AN INVESTIGATIONAL NEW DRUG APPLICATION TO BEGIN THIS TRIAL AND EXPECTS TO BEGIN ENROLLING PATIENTS IN MARCH 2020

* OSU AND KIADIS PLAN TO WORK TOGETHER TO INITIATE A COMPANY SPONSORED TRIAL WITH OFF—SHELF K-NK003 CELLS EXPANDED WITH KIADIS’ PARTICLE PRODUCTION PLATFORM (PM21) IN SAME PATIENT POPULATION LATER THIS YEAR Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below